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Background: Video-assisted thoracic surgery (VATS) lobectomy is a standard treatment for lung cancer. This study
retrospectively compared long-term outcomes after VATS lobectomy versus lobectomy via open thoracotomy for
clinical stage IA non-small cell lung cancer (NSCLC).
Methods: From July 2002 to June 2012, 160 patients were diagnosed with clinical stage IA NSCLC and underwent
lobectomy. Of these, 114 underwent VATS lobectomy and 46 underwent lobectomy via open thoracotomy.
Results: The 5-year disease-free survival (DFS) rate was 88.0% in the VATS group and 77.1% in the thoracotomy
group for clinical stage IA NSCLC (p = 0.1504), and 91.5% in the VATS group and 93.8% in the thoracotomy group
for pathological stage IA NSCLC (p = 0.2662). The 5-year overall survival (OS) rate was 94.1% in the VATS group and
81.8% in the thoracotomy group for clinical stage IA NSCLC (p = 0.0268), and 94.8% in the VATS group and 96.2% in
the thoracotomy group for pathological stage IA NSCLC (p = 0.5545). The rate of accurate preoperative staging was
71.9% in the VATS group and 56.5% in the thoracotomy group (p = 0.2611). Inconsistencies between the clinical
and pathological stages were mainly related to tumor size, nodal status, and pleural invasion. Local recurrence
occurred for one lesion in the VATS group and six lesions (five patients) in the thoracotomy group (p = 0.0495).
Conclusions: The DFS and OS were not inferior after VATS compared with thoracotomy. Local control was
significantly better after VATS than after thoracotomy. Preoperative staging lacked sufficient accuracy.
Keywords: Clinical stage IA, Lobectomy, Open thoracotomy, Prognosis, Video-assisted thoracic surgery (VATS)Background
Lung cancer is the leading cause of cancer-related deaths
worldwide [1]. Surgical resection of lung cancer in
patients without metastasis to other organs may provide
a long-term survival benefit compared with nonsurgical
therapies. Robert McKenna first described video-assisted
thoracic surgery (VATS) lobectomy in 1994 [2]. The
findings of many studies have established with reason-
able certainty that VATS lobectomy is associated with* Correspondence: higuchi@fmu.ac.jp
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unless otherwise stated.less postoperative pain, less postoperative morbidity, and
shorter hospital stay than lobectomy via open thora-
cotomy [3-6]. Several studies also reported that VATS
lobectomy is feasible and safe [4,5]. We started per-
forming VATS lobectomy in selected patients with
stage IA non-small cell lung cancer (NSCLC) in 2004.
After an initial learning curve period, we also started
performing this procedure in patients with stage IB
NSCLC, as we believed that the outcomes would not be
inferior to those after open thoracotomy. This study
compared the long-term survival outcomes after VATS
lobectomy versus lobectomy via open thoracotomy for
clinical stage IA NSCLC, and evaluated the current
concerns in these groups of patients.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patient characteristics
This retrospective study included 160 consecutive eligible
patients treated in the Department of Thoracic Surgery at
Fukushima Red Cross Hospital from July 2002 to June 2012.
The inclusion criteria were: VATS lobectomy or lobectomy
via open thoracotomy, with curative intent and without
preoperative induction chemotherapy or radiotherapy; and aTable 1 Patient characteristics









Squamous cell ca. 28(17.5)


























Surgery time (min.) 160(100)definitive postoperative diagnosis of stage IA NSCLC
according to the latest revision of the international sys-
tem for staging lung cancer [7]. The study included 89
females and 68 males. The hospital and office records of
each patient were reviewed and demographic and clin-
ical data were recorded, including age, sex, pathology,
clinical stage, and other clinicopathological factors.



































118.1 ± 154.3 321.6 ± 352.4 <0.0001
198.3 ± 50.2 205.1 ± 60.9 0.4662
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Declaration of Helsinki and Good Clinical Practice
guidelines. This study was approved by the Ethical
Committee of Fukushima Red Cross Hospital.
Preoperative staging
Preoperative investigations included thoracic and upper
abdominal computed tomography (CT) and brain mag-
netic resonance imaging (MRI) to establish absence
of multiple pulmonary lesions and absence of hepatic,
adrenal, or brain metastases; and to evaluate hilar and
mediastinal lymph node status. Bone scintigraphy was
performed if clinically indicated. F18-fluorodeoxyglu-
cose positron emission tomography (FDG-PET) was
performed within one month before surgery only when
a preoperative histological diagnosis could not be
obtained.
Surgical procedures
All patients underwent curative surgery by VATS lobec-
tomy or lobectomy via open thoracotomy. Patients were
placed in the lateral decubitus position with single-lung
ventilation. For VATS, a 10-mm, 30° thoracoscope was
introduced through the 7th intercostal space in the mid-
axillary line. A 2-cm incision was made in the 8th inter-
costal space in the auscultatory triangle. A 5-cm access
thoracotomy was usually placed in the 4th or 5th inter-
costal space in the anterior axillary line for upper/middle
or lower lobectomy, respectively. The pulmonary vessels
and bronchi were dissected as for open thoracotomy.
Branches of the pulmonary artery were ligated with 3–0
Vicryl (Ethicon, Somerville, NJ, USA) or stapled with a
linear stapler (Covidien, Mansfield, MA, USA). The
endoscopic linear stapler was used to divide pulmonary
veins and bronchi, and plication of the fissure. The
resected tissue was placed in a plastic specimen bag for
retrieval to avoid implantation of tumor cells. Lobec-
tomy via open thoracotomy was performed using a
20cm posterolateral incision sparing the serratus anter-
ior muscle, through the 4th or 5th intercostal space. The
vascular and bronchial structures were individuallyFigure 1 Five-year disease-free survival (DFS) (a) and overall survival
cancer (NSCLC). The 5-year DFS rate was 88.0% in the VATS group and 77
94.1% in the VATS group and 81.8% in the thoracotomy group (p = 0.0268)dissected and divided using endoscopic staplers.
Complete hilar and mediastinal lymph node dissection
was usually performed during both VATS and open thora-
cotomy. In patients with severe preoperative morbidity or
aged >80 years, only hilar dissection and mediastinal
lymph node sampling were performed. Resection was
considered complete when the resection margins were
free of disease. Pathological staging was performed ac-
cording to the 7th International Staging System for Lung
Cancer [7].
Histopathological examination
Tumors were evaluated by an experienced pathologist, and
graded according to the 2004 World Health Organization
classification for NSCLC. All specimens were formalin-
fixed, paraffin-embedded, and stained with hematoxylin
and eosin. Pleural invasion, lymphatic involvement,
and vascular involvement were determined by elastica-
Masson and hematoxylin and eosin staining.
Treatment and follow-up
Outpatient follow-up was performed by thoracic sur-
geons every 2–3 months until 12 months after surgery,
then every 6 months until 60 months, and then yearly.
Standard follow-up consisted of chest X-ray, laboratory
testing including measurement of tumor markers, and
clinical examination. Chest CT was performed every
6 months until 2 years, and then yearly. Further CT was
only performed if there were suspicious radiological,
serological, or clinical findings. Adjuvant chemotherapy
was administered to patients with adenocarcinoma if the
tumor measured >2.0 cm in diameter, using oral tegafur/
uracil (UFT™, Taiho Pharmaceuticals, Tokyo, Japan) for
2 years according to the Japanese standard adjuvant
chemotherapy regimen [8]. In patients with stage II or
more advanced stage NSCLC, vinorelbine (Navelbine™,
Kyowa Hakkou Kirin Co., Ltd, Tokyo, Japan) and cisplatin
(Randa™, Nippon Kayaku Co., Ltd, Tokyo, Japan) were
administered intravenously for four cycles according to
the report of the JBR.10 trial [9,10]. Adjuvant chemother-
apy was administered only to patients aged <75 years. The(OS) (b) for patients with clinical stage IA non-small-cell lung
.1% in the thoracotomy group (p = 0.1504), and the 5-year OS rate was
.
Figure 2 Five-year DFS (a) and OS (b) for patients with pathological stage IA NSCLC. The 5-year DFS rate was 91.5% in the VATS group and
93.8% in the thoracotomy group (p = 0.2662), and the 5-year OS rate was 94.8% in the VATS group and 96.2% in the thoracotomy group (p = 0.5545).
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Higuchi et al. Journal of Cardiothoracic Surgery 2014, 9:88 Page 4 of 7
http://www.cardiothoracicsurgery.org/content/9/1/88overall survival (OS) was estimated from the date of surgi-
cal resection until death of any cause or the date of last
follow-up. The disease-free survival (DFS) was estimated
from the date of surgical resection until tumor recurrence
or death from any cause. Local recurrence was defined as
recurrence in the pleural cavity or mediastinal or hilar
nodal stations. Distant recurrence was defined as recur-
rence in the distant organs or the ipsilateral or contralat-
eral lung.
Statistical analysis
Clinicopathological factors were compared between groups
using the two-tailed Pearson’s chi-square test. Survival
probabilities were estimated using the Kaplan–Meier
method. The significance of differences in disease-free
survival (DFS) between groups was tested using the
log-rank test. The univariate Cox proportional hazards
model was used to quantify the risk of recurrence as
a function of sex, age, histology, tumor size, and lobec-
tomy procedure. The multivariate Cox proportional
hazards model was used to identify independent predic-
tors of outcome after VATS lobectomy. All statistical ana-
lyses were performed using StatView 5.0 (SAS Institute,
Cary, NC, USA).
Results
Disease-free and overall survival
The median follow-up time was 44.8 months. The 5-
year DFS rate was 88.0% in the VATS group and 77.1%
in the thoracotomy group for clinical stage IA NSCLC








Tumor diameter > 3.0 cm 20 (12.5%) 14 (12.3%) 8 (17.4%)
pNl or pN2 19 (11.9%) 11 (9.6%) 8 (17.4%)
Positive pla 26 (16.3%) 17 (14.9%) 9 (19.6%)
apl: pleural invasion.and 93.8% in the thoracotomy group for pathological
stage IA NSCLC (p = 0.2662, Figure 2a). The 5-year OS
rate was 94.1% in the VATS group and 81.8% in the thora-
cotomy group for clinical stage IA NSCLC (p = 0.0268,
Figure 1b), and 94.8% in the VATS group and 96.2%
in the thoracotomy group for pathological stage IA
NSCLC (p = 0.5545, Figure 2b).
Accuracy of preoperative staging
The rate of accurate preoperative staging was 71.9%
in the VATS group and 56.5% in the thoracotomy group
(p = 0.2611). Inconsistencies between the clinical and
pathological stages were mainly related to tumor size
(12.3% and 17.4%), nodal metastasis (9.6% and 17.4%),
and pleural invasion (14.9% and 19.6%) in the VATS and
thoracotomy groups, respectively (Table 2).
Recurrence
Recurrence occurred after the initial resection of 27
lesions in 22 patients (Table 3). Distant metastasis
occurred after resection of 12 lesions (11 patients) in the
VATS group, and eight lesions (5 patients) in the thora-
cotomy group. Interestingly, local recurrence occurred
after resection of only one lesion in the VATS groupPulmonary metastasis 7 2
Brain metastasis 1 3
Bone metastasis 2 1
Hepatic metastasis 0 1
Others 2 1
Distant metastasis 12 8
Total 13 14
aLN: lymph node.
Table 4 Univariate analyses to identify factors associated with recurrence
VATS (n = l 14) Thoracotomy (n = 46)
n 5-year DFS (%) p n 5-year DFS (%) p
Gender 0.3422 0.993
Male 50 84.7 33 78.7
Female 64 87.2 13 73.6
Pathology 0.8159 0.3595
Adenocarcinoma 91 84.3 32 71
Squamous cell ca. 16 91.7 11 100
Others 7 83.3 3 50
Tumor diameter (cm) 0.5551 0.2765
≤3.0 100 88.2 40 75.7
3.0< 14 68.8 6 58.4
pN <0.0001 0.0136
N0 103 90.1 38 84.7
N1/N2 11 51.6 8 37.5
Pleural involvement 0.0174 0.0036
Negative 97 90.3 37 87
Positive 17 57.1 9 41.7
Lymphovascular involvement 0.0536 0.0118
Negative 93 88.6 27 91.6
Positive 21 73.8 19 53.7
Vascular involvement 0.4972 0.0096
Negative 92 87.2 29 88
Positive 22 79.7 17 58.1
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(p = 0.0495). Univariate analyses showed that recurrence
was associated with nodal metastasis (p < 0.0001 in the
VATS group, p = 0.0136 in the thoracotomy group) and
pleural invasion (p = 0.0174 in the VATS group, p = 0.0036
in the thoracotomy group). In the thoracotomy group,
recurrence was also associated with lymphatic involve-
ment (p = 0.0118) and vascular involvement (p = 0.0096)
(Table 4). Multivariate analyses showed that recurrenceTable 5 Multivariate analyses to identify factors
independently associated with recurrence in each group
a. VATS group
Variable Hazard ratio 95% CI. p
pN0 015 0.043-0.516 0.0026
Negative pla 0.389 0.111-1.369 0.1415
b. Thoracotomy group
Variable Hazard ratio 95% CI. p
pN0 0.243 0.049-1.210 0.0841
Negative pla 0.077 0.005-1.186 0.0986
Negative lyb 0.363 0.067-1.973 0.2407
Negative vc 0.893 0.138-5.764 0.9057
apl: pleural invasion, bly: lymphatic involvement, cv: vascular involvement.was independently associated with nodal metastasis
(p = 0.0026) in the VATS group, but was not independ-
ently associated with any factors in the thoracotomy
group (Table 5).
Discussion
VATS lobectomy is a minimally invasive technique for
anatomic pulmonary resection. In patients with NSCLC,
VATS lobectomy is associated with fewer complications
and faster recovery than open thoracotomy [4,5,11-14 ]. In
this study we also showed the significantly less bleeding in
VATS group compared with thoracotomy group (Table 1).
However, the most important parameter measuring the
success of any oncologic surgical resection is long-term
survival. The results of meta-analyses [13,14], randomized
trials [4,5], and large retrospective series [11,12] indicate
that this minimally invasive technique is safe and effective.
In this study, the 5-year OS and DFS rates in the VATS
group were not significantly inferior to those in the thora-
cotomy group for clinical stage IA NSCLC (Figure 1), and
OS was significantly better in the VATS group than in the
thoracotomy group. Whilston et al. [13] reviewed 39
studies that compared VATS lobectomy with lobectomy
via open thoracotomy. They found that patients who
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5-year survival rates compared with those who under-
went open thoracotomy. Yan et al. [14] performed a
similar systematic review and found that the 5-year
survival rate was significantly higher in patients who
underwent VATS lobectomy than those who underwent
open thoracotomy for early-stage NSCLC (VATS rela-
tive risk, 0.72; p = 0.04).
The significantly better OS in the VATS group reflects
the inaccurate preoperative diagnosis of clinical stage IA
NSCLC in some patients. Preoperative staging was based
on the findings of imaging examinations such as CT and
F18-fluorodeoxyglucose positron emission tomography.
The rate of accurate diagnosis of clinical stage IA
NSCLC was 71.9% in the VATS group and 56.5% in the
thoracotomy group (p = 0.2611). In both groups, incon-
sistencies between the clinical and pathological stages
were mainly related to lymph node status, pleural in-
volvement, and tumor size (Table 2). Stage migration oc-
curs when there is a difference between the clinical and
pathological T, N, or M stage, which occurs in up to
53% of patients who undergo resection of lung cancer
[15]. To improve the accuracy of preoperative staging,
imaging examination findings should be more precisely
evaluated, especially tumor size and lymph node status.
However, pleural involvement cannot be determined pre-
operatively, as this is diagnosed by pathological examin-
ation, even if preoperative CT shows pleural indentation.
It is therefore important to develop more effective
methods of determining pleural invasion on preopera-
tive imaging examinations. It should also be kept in
mind that selection bias influences the rate of accurate
diagnosis of clinical stage IA NSCLC. For example,
VATS lobectomy is considered preferable in female
patients with small adenocarcinomas, whereas male pa-
tients with squamous cell carcinoma are less likely to be
selected for VATS lobectomy because they may have
emphysematous lungs and non-specific lymph node
enlargement due to heavy smoking or their working
history, which may increase the difficulty of surgery.
During the early period of performing VATS lobectomy,
we may have avoided preforming VATS in the latter
group of patients. The significant differences in sex
distribution, lymphatic involvement, and vascular in-
volvement between the VATS and thoracotomy groups
may reflect such a bias (Table 1). Furthermore, the
much higher rate of nodal upstaging in the thoracotomy
group than in the VATS group may reflect dissection of
a lower number of lymph nodes, or inadequate dissec-
tion of lymph nodes, during VATS lobectomy compared
with open thoracotomy in patients with clinical stage IA
NSCLC. However, we did not evaluate the number of
dissected lymph nodes in each group. Merritt et al. [16]
reported that lymph node dissection may be inadequateduring VATS lobectomy. Boffa et al. [17] also showed
the incompleteness of the peribronchial and hilar node
evaluation in the VATS group. In this study, upstaging
from N0 to N1 or N2 was more common in the thora-
cotomy group (17.4% versus 9.6%, p=0.1706) as with
previous reports [17]. However, this study found that local
control was better in the VATS group, and the prognosis of
patients with pathological stage I NSCLC was not signifi-
cantly different between the VATS and thoracotomy
groups. These results suggest that VATS lobectomy is a
feasible treatment for pathological stage IA NSCLC and in-
dicate that differences in nodal upstaging result from pa-
tient selection. However, this study found that local control
was better in the VATS group, and the prognosis of pa-
tients with pathological stage I NSCLC was not signifi-
cantly different between the VATS and thoracotomy
groups. These results suggest that VATS lobectomy is a
feasible treatment for pathological stage IA NSCLC. Multi-
variate analysis indicated that the accuracy of preoperative
staging is the most important factor needed to improve the
prognosis of VATS lobectomy for clinical stage IA NSCLC.
Some centers have reported that they perform all
pulmonary surgical procedures by VATS, including
pulmonary artery reconstruction and bronchoplasty
[18,19]. Our center currently uses VATS lobectomy only
for clinical stage IA and IB NSCLC, but we may be able
to extend the indications for this procedure to more
advanced cases of NCSLC. The long-term outcomes
after VATS lobectomy still require further evaluation.
The present study is limited by its retrospective nature,
and a larger prospective randomized study is required
to reach definitive conclusions regarding the efficacy of
VATS lobectomy for the treatment of NSCLC.
Conclusions
The DFS and OS were not inferior after VATS compared
with thoracotomy in clinical stage I NSCLC. Local control
was significantly better after VATS than after thoracotomy.
However, preoperative staging lacked sufficient accuracy.
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